Plaque Psoriasis Market Epidemiology, Size, Trends, and Forecast 2025-2035
The 7 major plaque psoriasis markets reached a value of USD 12.7 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 32.3 Billion by 2035, exhibiting a growth rate (CAGR) of 8.89% during 2025-2035.
Currently, plaque psoriasis is diagnosed in millions of people as one of the most common autoimmune skin disorders due to its distinguishable red, scaly patches. With the advancement in technology and patient needs, the treatment landscape is changing for the better as we approach the year of 2025. Not only does this pose better prospects for managing the disease, but offers hope for the expanding global plaque psoriasis market.
Current Treatment Landscape and Market Dynamics
The advancements in medicine offer a variety of therapeutic choices including topical and whole body systemic treatment. Patients suffering from mild plaque psoriasis are often put on corticosteroid and vitamin D analog therapy which remain first line treatments. More advanced cases tend to require systemic medication or biologics. Unlike traditional therapies, the newer biologic drugs which have dominated the market in recent years are more precise as they focus on specific immune system pathways.
The care provided to patients suffering from psoriasis has drastically changed in the last few years, thanks to the invention of interleukin inhibitors. IL-17, IL-23 and TNF-alpha targeting drugs have proven to work impressively with some patients completely clearing their skin. Though many people suffering from plaque psoriasis are greatly aided with the advancements so far, the lack of accessibility and the ever rising cost of treatment makes it a challenge.
Innovative Changes Influencing the Market in 2025
A variety of important changes are expected to transform the strategies for managing plaque psoriasis by 2025. Convenience remains paramount, and newer options like JAK and PDE4 inhibitors’ oral therapies are systemically treating patients with ease. There are a number of promising candidates in the pipeline that may provide viable alternatives to injectable biologic therapies.
The concept of personalized medicine is starting to take hold in the treatment of psoriasis. Genetic and biomarker analyses are making it increasingly possible for clinicians to predict treatment responses, allowing for more customized therapeutic strategies. This pivot towards precision medicine will help maximize results while minimizing multiple medication attempts.
By 2025, the market for biosimilars is projected to witness remarkable growth, which may enhance treatment accessibility. As the patents of key biologics are going to be available, there will be considerable competition among biosimilars, thus significantly decreasing the cost and increasing the availability of advanced therapies in both developed and developing countries.
Digital health technologies are being adopted into psoriasis care and management. Telehealth platforms, AI enabled diagnostic tools, and mobile symptom tracking applications are streamlining patient monitoring and treatment compliance. These advancements hold significant promise in the management of chronic diseases by making care more proactive.
Market Analysis and Estimation Opportunities for Growth
The North American region leads the global plaque psoriasis market due to high treatment awareness, healthcare infrastructure, R&D investment, and psychographic factors. Europe is in second place without much distance behind, expanding focus on low-cost treatment alternatives. The Asia-Pacific region is expected to be the most dynamic in terms of growth, due to increased accessibility to healthcare facilities, improving general awareness, and increasing prevalence of the condition.
Barriers to Improving Treatment and Challenges
There is an ever-present progress in plaque psoriasis; however, the market is confronted with a number of obstacles. Most patients currently face challenges with treatment costs, particularly with newer biologics. Additionally, the side effect profile alongside safety monitoring for the long-term continues to remain critical factors for most clinicians when choosing treatments. A large number of patients remain unable to find complete and adequate therapies that offer durable relief.
In synonyms, innovative research is being conducted on mechanisms that bypass cytokine interventions. Other inflammatory mediators such as the IL-36 pathway are currently being investigated in the clinical setting. Alongside this focus, combination therapies and sequential treatment approaches are being revised to improve sustained results over time.
Request for a sample of this report: https://www.imarcgroup.com/plaque-psoriasis-market/requestsample
Countries Covered:
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country:
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the plaque psoriasis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the plaque psoriasis market
Reimbursement scenario in the market
In-market and pipeline drugs
This report also provides a detailed analysis of the current plaque psoriasis market drugs and late-stage pipeline drugs.
In-Market Drugs:
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
Drug overview
Mechanism of action
Regulatory status
Clinical trial results
Drug uptake and market performance
Competitive Landscape with key players:
The competitive landscape of the plaque psoriasis market has been studied in the report with the detailed profiles of the key players operating in the market.
1.Amgen
Ortho Dermatologics
Ortho Dermatologics
Sun Pharmaceutical Industries
Arcutis Biotherapeutics
Affibody
Alumis
Janssen
9.Takeda
- MetrioPharm
Ask the Analyst for Customization and Explore the Full Report with TOC: https://www.imarcgroup.com/request?type=report&id=7500&flag=A
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
